Persistence of Bactericidal Activity at 4 Years After 2 Primary Doses of a Recombinant, 4-Component, Meningococcal Serogroup B Vaccine (4CMenB) and Response to a Booster Dose in Adolescents and Young Adults
نویسندگان
چکیده
1060. Persistence of Bactericidal Activity at 4 Years After 2 Primary Doses of a Recombinant, 4-Component, Meningococcal Serogroup B Vaccine (4CMenB) and Response to a Booster Dose in Adolescents and Young Adults Terry Nolan, MBBS PhD; Hartley Garfield, MD; Anil Gupta, MD CCFP; Murdo Ferguson, MBChB; Helen Marshall, MD MBBS; Diego D’Agostino, MSc and Daniela Toneatto, MD; University of Melbourne and Murdoch Children’s Research Institute, Melbourne, Victoria, Australia, University of Toronto, Toronto, ON, Canada, Colchester Research Group, Truro, NS, Canada, University of Adelaide and Women’s and Children’s Hospital, Adelaide, South Australia, Australia, GSK, Amsterdam, Netherlands, GSK, Siena, Italy
منابع مشابه
Vaccinating High-Risk Pediatric Patients and Their Families in the Hospital Setting: Give It a Shot!
1060. Persistence of Bactericidal Activity at 4 Years After 2 Primary Doses of a Recombinant, 4-Component, Meningococcal Serogroup B Vaccine (4CMenB) and Response to a Booster Dose in Adolescents and Young Adults Terry Nolan, MBBS PhD; Hartley Garfield, MD; Anil Gupta, MD CCFP; Murdo Ferguson, MBChB; Helen Marshall, MD MBBS; Diego D’Agostino, MSc and Daniela Toneatto, MD; University of Melbourn...
متن کاملPersistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.
BACKGROUND The multicomponent serogroup B meningococcal (4CMenB) vaccine was recently licensed for use in Europe. There are currently no data on the persistence of bactericidal antibodies induced by use of this vaccine in infants. Our objective was to evaluate serogroup B-specific bactericidal antibodies in children aged 40-44 months previously vaccinated at 2, 4, 6 and 12 months of age. METH...
متن کاملA Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
Recently approved in Europe and Australia, the multi-component meningococcal B vaccine, 4CMenB (Bexsero®, Novartis Vaccines and Diagnostics), contains three surface-exposed recombinant proteins (fHbp, NadA, and NHBA) and New Zealand strain outer membrane vesicles (NZ OMV) with PorA 1.4 antigenicity. This comprehensive review of the 4CMenB clinical development program covers pivotal phase I/IIb/...
متن کاملPersistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months.
BACKGROUND The multicomponent serogroup B meningococcal (4CMenB) vaccine induces antibodies against indicator strains of serogroup B meningococcus under various schedules. We investigated the persistence of antibodies in 5-year-old children 18-20 months after their last dose (at about 3.5 years of age). METHODS We assessed 5-year-old children who received the 4CMenB vaccine or a recombinant p...
متن کاملSerogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization.
BACKGROUND The persistence of protection from meningococcal disease following immunization with serogroup C meningococcal (MenC) glycoconjugate vaccines in infancy is short-lived. The duration of protective immunity afforded by these vaccines in other at-risk age groups (i.e., adolescents and young adults) is not known. We evaluated the persistence of bactericidal antibodies following immunizat...
متن کامل